Anzeige
Meldung des Tages: Diese Kupfer-News kam leise – KI, Energie, Defense: Warum jetzt plötzlich alles an Kupfer hängt

Neurocrine Biosc. News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
128,30 $
-4,15 $
-3,13%
111,45 € 27.03.26
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
Nachhaltigkeits-Score
55 %
Index-Zuordnung
-

Neurocrine Biosciences News

06.10.25 - PR Newswire
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences Presents New Three-​Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for ...
23.09.25 - PR Newswire
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While ...
22.09.25 - PR Newswire
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder PR Newswire
16.09.25 - PR Newswire
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 PR Newswire
26.08.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire
06.08.25 - PR Newswire
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference PR Newswire
30.07.25 - PR Newswire
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results PR Newswire
15.07.25 - PR Newswire
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition PR Newswire
15.07.25 - PR Newswire
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid ...
14.07.25 - PR Newswire
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-​Related Effects of Glucocorticoid Treatment at the 2025 ...
14.07.25 - PR Newswire
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 PR Newswire
09.07.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results PR Newswire
30.06.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-​Acting Corticotropin-​Releasing Factor Type 1 Receptor Antagonist PR Newswire
27.06.25 - PR Newswire
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) ...
20.06.25 - PR Newswire
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Neurocrine Biosciences Presents New Data Showing Significant Patient-​Reported Improvements in Health-​Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older ...
09.06.25 - PR Newswire
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer PR Newswire
02.06.25 - PR Newswire
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
Neurocrine Biosciences Presents Patient-​Reported Outcomes from KINECT-​PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of ...
16.05.25 - PR Newswire
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
Neurocrine Biosciences to Present Wide-​Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting PR Newswire
16.05.25 - PR Newswire
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia PR ...
15.05.25 - PR Newswire
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal ...

Newssuche

Videos

newspaper
23.03.26 +6,96%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »